Northwest Biotherapeutics Files 2024 10-K
Ticker: NWBO · Form: 10-K · Filed: 2025-03-31T00:00:00.000Z
Sentiment: neutral
Topics: 10-K, financials, warrants
TL;DR
NWBO 2024 10-K filed. Warrant liability $7.32M. Investors watch valuation inputs.
AI Summary
Northwest Biotherapeutics Inc. reported its 2024 fiscal year results, ending December 31, 2024. The company's filing indicates significant financial activities, including warrant liabilities valued at $7.32 million, with associated risk-free interest rates, price volatility, and expected term inputs for fair value calculations as of December 31, 2024. The company is based in Bethesda, MD.
Why It Matters
This filing provides a year-end financial snapshot for Northwest Biotherapeutics, crucial for investors assessing the company's financial health and valuation, particularly concerning its warrant liabilities.
Risk Assessment
Risk Level: medium — The company's financial disclosures, particularly regarding warrant liabilities and their valuation inputs, suggest a level of financial complexity and potential volatility.
Key Numbers
- $7.32M — Warrant Liability (Fair value of outstanding warrants as of December 31, 2024.)
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K filing.)
Key Players & Entities
- NORTHWEST BIOTHERAPEUTICS INC (company) — Filer
- 2024-12-31 (date) — Fiscal Year End
- $7.32 million (dollar_amount) — Warrant Liability Value
- BETHESDA, MD (location) — Company Headquarters
FAQ
What was the total revenue for Northwest Biotherapeutics in the fiscal year ending December 31, 2024?
The provided snippet does not contain specific total revenue figures for the fiscal year ending December 31, 2024.
What is the nature of the 'Warrant Liability' mentioned and how is it valued?
The filing mentions a 'Warrant Liability' valued at $7.32 million as of December 31, 2024, with valuation inputs including risk-free interest rate, price volatility, and expected term.
What are the key inputs used for the fair value measurement of the warrant liability?
The key inputs for the fair value measurement of the warrant liability include the risk-free interest rate, price volatility, and expected term, categorized under 'FairValueInputsLevel3Member'.
Where is Northwest Biotherapeutics Inc. headquartered?
Northwest Biotherapeutics Inc. is headquartered in Bethesda, MD, with its business and mailing addresses listed at 4800 Montgomery Lane, Suite 800.
What is the SEC file number for this 10-K filing?
The SEC file number for this 10-K filing is 001-35737.
From the Filing
0001410578-25-000598.txt : 20250331 0001410578-25-000598.hdr.sgml : 20250331 20250331172324 ACCESSION NUMBER: 0001410578-25-000598 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 95 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250331 DATE AS OF CHANGE: 20250331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NORTHWEST BIOTHERAPEUTICS INC CENTRAL INDEX KEY: 0001072379 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 943306718 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35737 FILM NUMBER: 25795126 BUSINESS ADDRESS: STREET 1: 4800 MONTGOMERY LANE STREET 2: SUITE 800 CITY: BETHESDA STATE: MD ZIP: 20814 BUSINESS PHONE: (240) 497-9024 MAIL ADDRESS: STREET 1: 4800 MONTGOMERY LANE STREET 2: SUITE 800 CITY: BETHESDA STATE: MD ZIP: 20814 10-K 1 nwbo-20241231x10k.htm 10-K NORTHWEST BIOTHERAPEUTICS INC_December 31, 2024 http://www.nwbio.com/20241231#ResearchAndOtherRevenueMember http://fasb.org/us-gaap/2024#RelatedPartyMember 0001072379 --12-31 2024 FY false http://fasb.org/us-gaap/2024#RelatedPartyMember 0 0 0 0 0 0 0 0 0 0 NORTHWEST BIOTHERAPEUTICS INC NONE http://www.nwbio.com/20241231#ResearchAndOtherRevenueMember http://fasb.org/us-gaap/2024#DerivativeGainLossOnDerivativeNet http://fasb.org/us-gaap/2024#DerivativeGainLossOnDerivativeNet P6M http://fasb.org/us-gaap/2024#RelatedPartyMember 7.32 689000 550000 http://fasb.org/us-gaap/2024#RelatedPartyMember 0.04 0.04 400000 0001072379 us-gaap:FairValueInputsLevel3Member nwbo:WarrantLiabilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0001072379 us-gaap:FairValueInputsLevel3Member nwbo:WarrantLiabilityMember us-gaap:MeasurementInputPriceVolatilityMember 2024-12-31 0001072379 us-gaap:FairValueInputsLevel3Member nwbo:WarrantLiabilityMember us-gaap:MeasurementInputExpectedTermMember 2024-12-31 0001072379 us-gaap:FairValueInputsLevel3Member nwbo:WarrantLiabilityMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-12-31 0001072379 us-gaap:FairValueInputsLevel3Member nwbo:WarrantLiabilityMember us-gaap:MeasurementInputExercisePriceMember 2024-12-31 0001072379 nwbo:AugustSeptemberConvertibleNotesMember 2023-12-31 0001072379 nwbo:SeriesCConvertiblePreferredStockMember 2022-07-20 0001072379 nwbo:SeriesCConvertiblePreferredStockMember 2024-12-31 0001072379 nwbo:SeriesCConvertiblePreferredStockMember 2023-12-31 0001072379 nwbo:SeriesCConvertiblePreferredStockMember 2022-12-31 0001072379 us-gaap:RetainedEarningsMember 2024-12-31 0001072379 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001072379 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001072379 nwbo:SubscriptionReceivableMember 2024-12-31 0001072379 us-gaap:RetainedEarningsMember 2023-12-31 0001072379 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001072379 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001072379 nwbo:SubscriptionReceivableMember 2023-12-31 0001072379 us-gaap:RetainedEarningsMember 2022-12-31 0001072379 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001072379 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001072379 nwbo:SubscriptionReceivableMember 2022-12-31 0001072379 us-gaap:CommonStockMember 2024-12-31 0001072379 us-gaap:CommonStockMember 2023-12-31 0001072379 us-gaap:CommonStockMember 2022-12-31 0001072379 nwbo:SeriesCInvestorsMember nwbo:SeriesCConvertiblePreferredStockMember nwbo:SeriesCSubscriptionAgreementsMember 2024-12-31 0001072379 nwbo:PlacementAgentWarrantMember nwbo:JuneOfferingMember 2024-06-04 0001072379 nwbo:SeriesCInvestorsMember nwbo:SeriesCConvertiblePreferredStockMember nwbo:SeriesCSubscriptionAgreementsMember 2023-12-31 0001072379 srt:MinimumMember 2023-01-01 2023-12-31 0001072379 srt:MaximumMember 2023-01-01 2023-12-31 0001072379 nwbo:PreModificationMember 2024-01-01 2024-12-31 0001072379 nwbo:PreModificationMember 2023-01-01 2023-12-31 0001072379 nwbo:PreModificat